Prophilian helps to evaluate and improve the performance of drugs through two subsidiaries. Pharmaceutical Profiles studies how drugs are absorbed by the body, while Phaeton looks at ways of improving the process. Together they aim to help pharmaceutical companies save time and money in developing new drugs. The venture-capital firm 3i invested £500,000 in Prophilian in 1999. Pharmaceutical Profiles was founded in 1990 as a spin-out from the University of Nottingham and the Royal Free Hospital. Its sales have grown 75% a year from £2.9m in 2000 to £9m in 2002.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.